P1111 Two Years on Linaclotide: Tolerability and Treatment Satisfaction in IBS-C Patients With and Without Diarrhea

William D. Chey, MD, FACG
William D. Chey, MD, FACG

Author insight from William D. Chey, MD, FACG, University of Michigan, Ann Arbor, MI

What’s new here and important for clinicians?

  • In an 18 month long term safety study which included over 500 IBS-C patients, 32% reported diarrhea as an adverse event.
  • The diarrhea was reported to be mild (47%) to moderate (47%) in 94% of patients.
  • Over half reported their diarrhea in the first 2 weeks of treatment.
  • 76% of those reporting diarrhea either reduced their dose and/or suspended treatment but only 3% (17/535) withdrew from the study as a result of diarrhea.
  • Patients with and without a diarrhea adverse event (AE) reported similar levels of satisfaction with linaclotide therapy.

What do patients need to know?

Diarrhea is the most common side effect with linaclotide – it is usually mild to moderate in severity and tends to happen within a couple of weeks of initiating therapy. Severe diarrhea is rare.

Read abstract


Author Contact
William D. Chey, MD, FACG, University of Michigan, Ann Arbor, MI

Related Abstracts

Oral 12 Analysis of Exhaled Volatile Organic Compounds Reveals New Biomarkers for Irritable Bowel Syndrome
P506 Understanding Gender Differences in IBS: The Role of Stress From the Social Environment
P1719 Regional Variation of Care for Irritable Bowel Syndrome in the United States
P1718 Age-Related Health Care Disparities in Patients With Irritable Bowel Syndrome: Findings From a Sample of Commercially Insured Patients
P1110 Cognitive Behavioral Self-Help for Irritable Bowel Syndrome
P1117 What Strategies Do Patients With Irritable Bowel Syndrome Continue to Use Following a 9-Week Comprehensive Self-Management Program?

Media Interview Requests:

To arrange an interview with any ACG experts or abstract authors please contact Jacqueline Gaulin of ACG via email jgaulin@gi.org or by phone at 301-263-9000.